Both Tak1fl/fl (p < 0.05) and Cx3cr1creER-Tak1fl/fl mice (p < 0.01) gained clinical benefits from EPO administration over the entire observation period of 72 h after stroke. This evidence concerns the gene EPO and stroke disorder.